Mesa Laboratories Inc.
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: mesalabs.com
Recent Analyst Ratings for Mesa Laboratories Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $120.00 | Underweight | Wells Fargo |
| 1/4/2024 | $100.00 → $125.00 | In-line → Outperform | Evercore ISI |
Mesa Laboratories Inc. Press Releases
Fastest customizable press release news feed in the world
Mesa Labs Announces Third Quarter Results
LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q25") ended December 31, 2024 (amounts in thousands). Third quarter FY 2025 compared to third quarter FY 2024: Revenues increased 17.5%Non-GAAP core organic revenues1 increase was 13.2%Operating income increased 8,725% to $5,779Non-GAAP adjusted operating income excluding unusual items2 increased 13.3% and was 23.5% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 4, 2025
LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. CONTACT: Gary Owens, President and
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
Mesa Labs Announces Second Quarter Results
LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter ("2Q25") ended September 30, 2024 (amounts in thousands). Second quarter FY 2025 compared to second quarter FY 2024: Revenues increased 8.8%Non-GAAP core organic revenues¹ decline was 2.8%Operating income increased 5,947% to $3,508 Non-GAAP adjusted operating income excluding unusual items² increased 18.9% and was 24.8% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Cl
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
Mesa Labs Announces First Quarter Results
LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter ("1Q25") ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024: Revenues increased 14.9%Non-GAAP core organic revenues1 growth was 3.0%Operating income increased 940%Non-GAAP adjusted operating income excluding unusual items2 increased 47.0% and was 26.4% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Clinical Genomics ("
MESA LABS DECLARES QUARTERLY DIVIDEND
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results
LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q24") and fiscal year ("FY24") ended March 31, 2024 (amounts in thousands). Fourth quarter FY24 compared to fourth quarter FY23: Revenues increased 6% and increased 10.2% vs 3Q24Non-GAAP core organic revenues1 decreased 3.5%Operating (loss) was $(271,284) which included a $274,533 non-cash impairment chargeNon-GAAP adjusted operating income excluding unusual items2 increased 26.3% and was 25.4% as a percentage of revenues Full
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES
Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced the closing of its Amended and Restated Credit Agreement (the "Credit Agreement"), which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A. The Credit Agreement includes a $75 million senior secured term loan facility (the "Term Loan") and a $125 million senior secured revolving credit facility (the "Revolver"), both of which mature in April 2029. The Credit Agreement includes a ten-year amortization schedule and no springing maturity relating to the Company's 1.375% Convertible Senior
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
Mesa Laboratories Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wells Fargo initiated coverage on Mesa Laboratories with a new price target
Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00
Mesa Laboratories upgraded by Evercore ISI with a new price target
Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously
Mesa Laboratories Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
President and CEO Owens Gary M exercised 21,000 shares at a strike of $122.98 and sold $2,602,110 worth of shares (21,000 units at $123.91) (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
Director Sullivan John James gifted 2,000 shares, decreasing direct ownership by 7% to 25,878 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
President and CEO Owens Gary M was granted 11,559 shares and sold $571,736 worth of shares (5,069 units at $112.79), increasing direct ownership by 18% to 43,337 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
SVP Operations Archbold Brian David sold $187,375 worth of shares (1,499 units at $125.00), closing all direct ownership in the company (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
CFO Sakys John converted options into 1,037 shares and covered exercise/tax liability with 454 shares, increasing direct ownership by 5% to 12,046 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
President and CEO Owens Gary M converted options into 3,301 shares and covered exercise/tax liability with 1,445 shares, increasing direct ownership by 5% to 36,847 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
SVP Operations Archbold Brian David converted options into 845 shares and covered exercise/tax liability with 386 shares, increasing direct ownership by 44% to 1,499 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
Director Sullivan John James converted options into 1,074 shares, increasing direct ownership by 4% to 27,878 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
Director Tripeny R Tony converted options into 1,074 shares, increasing direct ownership by 67% to 2,679 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
Director Ladiwala Shiraz Shabanali converted options into 1,574 shares, increasing direct ownership by 105% to 3,074 units (SEC Form 4)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
Mesa Laboratories Inc. SEC Filings
SEC Form 10-Q filed by Mesa Laboratories Inc.
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
Mesa Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
SEC Form 10-Q filed by Mesa Laboratories Inc.
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
Mesa Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
Mesa Laboratories Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
SEC Form 10-Q filed by Mesa Laboratories Inc.
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
Mesa Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
SEC Form DEF 14A filed by Mesa Laboratories Inc.
DEF 14A - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
SEC Form 10-K filed by Mesa Laboratories Inc.
10-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
SEC Form NT 10-K filed by Mesa Laboratories Inc.
NT 10-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
Mesa Laboratories Inc. Leadership Updates
Live Leadership Updates
Mesa Laboratories Appoints Mark Capone to its Board of Directors
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us", or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the "Board"), effective January 5, 2024. Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: "We are pleased to welcome Mark to Mesa's Board. Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics. We believe Mark's insights will be pivotal to Mesa
Mesa Laboratories, Inc. Appoints Shiraz Ladiwala as Lead Independent Director
LAKEWOOD, Colo., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or the "Company") today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors ("Board"), effective November 3, 2022. Mr. Ladiwala assumes this newly re-created role as an expansion of his current responsibilities on the Board, on which he has served since October 2021. Mr. Ladiwala was selected for this important role due to the thoughtful leadership and contributions he has made to the Board as well as the exceptional breadth of his professional experience. Mr. Ladiwala said, "I am delighted to accept this leadership role on Mes
Mesa Laboratories Appoints Tony Tripeny to its Board of Directors
LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the "Board"), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr. Tripeny's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. Mr. Tripeny is likely to be appointed to the Audit Committee and brings extensive financial experience to the Board. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent
Leader in Corporate Development and Strategy Joins Mesa Labs Board of Directors
LAKEWOOD, Colo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021. Shiraz previously worked in leadership roles at Thermo Fisher Scientific and retired on August 31, 2021. With Mr. Ladiwala's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. "Shiraz's extensive experience building a world class life sciences company and his knowledge in corporate development and the Asia/ Pacific region will be instrumental to helping Mesa achieve its strategic objectives" said John Sullivan, Ph.D
Mesa Labs Declares Quarterly Dividend
LAKEWOOD, Colo., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa Labs” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2021, to shareholders of record at the close of business on February 26, 2021. About Mesa Laboratories, Inc.Mesa Labs is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, medical device, industrial safety, environmental, and food and beverage industries. Mesa Labs offers products and services through four divisions (St
Mesa Laboratories Inc. Financials
Live finance-specific insights
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
MESA LABS DECLARES QUARTERLY DIVIDEND
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product
Mesa Labs Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels to Mesa's SDC Platform
Lakewood, Colo., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us" or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the completed acquisition of GKE-GmbH's sterilization indicators business and its accredited, independent testing lab SAL GmbH. Additionally, Mesa has entered into a definitive agreement to purchase GKE's Chinese sales entity, Beijing GKE Science & Technology Co. LTD ("GKE China"). The total purchase price for the acquisition of the three entities is €85M (of which €5M is associated with GKE China), which is subject to customary purchase price adj
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, i
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., July 05, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integ
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., April 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2023, to shareholders of record at the close of business on May 31, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase
Mesa Labs Declares Quarterly Dividend
LAKEWOOD, Colo., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, incr
Mesa Laboratories Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Mesa Laboratories Inc.
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)